Stereotactic radiotherapy for polypoidal choroidal vasculopathy: A pilot study

Ugo Introini, Giuseppe Casalino, Giacinto Triolo, Denis O'Shaughnessy, E. Mark Shusterman, Usha Chakravarthy, Jason S. Slakter, Francesco Bandello

Research output: Contribution to journalArticle

Abstract

Purpose: To evaluate low-voltage X-ray stereotactic radiotherapy (SRT) delivered in conjunction with intravitreal ranibizumab for the treatment of active macular polypoidal choroidal vasculopathy (PCV). Methods: At baseline, all eyes received an intravitreal injection of ranibizumab, followed by 16-Gy X-ray SRT to the macula. Further ranibizumab injections were given pro re nata. The primary outcome measure was regression of the polyps assessed by indocyanine green angiography. Secondary outcome measures were best-corrected visual acuity (BCVA) and central foveal thickness (CFT) changes on optical coherence tomography. Local or systemic adverse events were evaluated as well. Results: We examined 12 eyes of 12 patients with PCV. At month 12, an angiographic regression of the polyps was observed in 10 of the 12 eyes. The mean BCVA improved by 7.6 letters: from 65.08 ± 11.4 to 72.7 ± 14.75 letters on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart. The mean CFT decreased from 372.3 ± 79.6 to 215.9 ± 57.9 μm (p <0.01). No local or systemic adverse events were reported. Conclusions: The preliminary data support the safety of low-voltage X-ray SRT for the treatment of macular PCV and show polyp closure, reduction in CFT and improvement in the mean BCVA. Additional research is warranted to confirm the efficacy and longer-term safety of this therapy in this population.

Original languageEnglish
Pages (from-to)82-88
Number of pages7
JournalOphthalmologica
Volume233
Issue number2
DOIs
Publication statusPublished - Mar 6 2015

Fingerprint

Radiotherapy
Polyps
Visual Acuity
X-Rays
Outcome Assessment (Health Care)
Safety
Intravitreal Injections
Indocyanine Green
Optical Coherence Tomography
Diabetic Retinopathy
Therapeutics
Angiography
Injections
Research
Population
Ranibizumab

Keywords

  • Age-related macular degeneration
  • Indocyanine green angiography
  • Intravitreal ranibizumab
  • Polypoidal choroidal vasculopathy
  • Stereotactic radiotherapy

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Medicine(all)

Cite this

Introini, U., Casalino, G., Triolo, G., O'Shaughnessy, D., Shusterman, E. M., Chakravarthy, U., ... Bandello, F. (2015). Stereotactic radiotherapy for polypoidal choroidal vasculopathy: A pilot study. Ophthalmologica, 233(2), 82-88. https://doi.org/10.1159/000368561

Stereotactic radiotherapy for polypoidal choroidal vasculopathy : A pilot study. / Introini, Ugo; Casalino, Giuseppe; Triolo, Giacinto; O'Shaughnessy, Denis; Shusterman, E. Mark; Chakravarthy, Usha; Slakter, Jason S.; Bandello, Francesco.

In: Ophthalmologica, Vol. 233, No. 2, 06.03.2015, p. 82-88.

Research output: Contribution to journalArticle

Introini, U, Casalino, G, Triolo, G, O'Shaughnessy, D, Shusterman, EM, Chakravarthy, U, Slakter, JS & Bandello, F 2015, 'Stereotactic radiotherapy for polypoidal choroidal vasculopathy: A pilot study', Ophthalmologica, vol. 233, no. 2, pp. 82-88. https://doi.org/10.1159/000368561
Introini U, Casalino G, Triolo G, O'Shaughnessy D, Shusterman EM, Chakravarthy U et al. Stereotactic radiotherapy for polypoidal choroidal vasculopathy: A pilot study. Ophthalmologica. 2015 Mar 6;233(2):82-88. https://doi.org/10.1159/000368561
Introini, Ugo ; Casalino, Giuseppe ; Triolo, Giacinto ; O'Shaughnessy, Denis ; Shusterman, E. Mark ; Chakravarthy, Usha ; Slakter, Jason S. ; Bandello, Francesco. / Stereotactic radiotherapy for polypoidal choroidal vasculopathy : A pilot study. In: Ophthalmologica. 2015 ; Vol. 233, No. 2. pp. 82-88.
@article{9b2f8a51b7a54a0ba498bac09a637a37,
title = "Stereotactic radiotherapy for polypoidal choroidal vasculopathy: A pilot study",
abstract = "Purpose: To evaluate low-voltage X-ray stereotactic radiotherapy (SRT) delivered in conjunction with intravitreal ranibizumab for the treatment of active macular polypoidal choroidal vasculopathy (PCV). Methods: At baseline, all eyes received an intravitreal injection of ranibizumab, followed by 16-Gy X-ray SRT to the macula. Further ranibizumab injections were given pro re nata. The primary outcome measure was regression of the polyps assessed by indocyanine green angiography. Secondary outcome measures were best-corrected visual acuity (BCVA) and central foveal thickness (CFT) changes on optical coherence tomography. Local or systemic adverse events were evaluated as well. Results: We examined 12 eyes of 12 patients with PCV. At month 12, an angiographic regression of the polyps was observed in 10 of the 12 eyes. The mean BCVA improved by 7.6 letters: from 65.08 ± 11.4 to 72.7 ± 14.75 letters on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart. The mean CFT decreased from 372.3 ± 79.6 to 215.9 ± 57.9 μm (p <0.01). No local or systemic adverse events were reported. Conclusions: The preliminary data support the safety of low-voltage X-ray SRT for the treatment of macular PCV and show polyp closure, reduction in CFT and improvement in the mean BCVA. Additional research is warranted to confirm the efficacy and longer-term safety of this therapy in this population.",
keywords = "Age-related macular degeneration, Indocyanine green angiography, Intravitreal ranibizumab, Polypoidal choroidal vasculopathy, Stereotactic radiotherapy",
author = "Ugo Introini and Giuseppe Casalino and Giacinto Triolo and Denis O'Shaughnessy and Shusterman, {E. Mark} and Usha Chakravarthy and Slakter, {Jason S.} and Francesco Bandello",
year = "2015",
month = "3",
day = "6",
doi = "10.1159/000368561",
language = "English",
volume = "233",
pages = "82--88",
journal = "Ophthalmologica",
issn = "0030-3755",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Stereotactic radiotherapy for polypoidal choroidal vasculopathy

T2 - A pilot study

AU - Introini, Ugo

AU - Casalino, Giuseppe

AU - Triolo, Giacinto

AU - O'Shaughnessy, Denis

AU - Shusterman, E. Mark

AU - Chakravarthy, Usha

AU - Slakter, Jason S.

AU - Bandello, Francesco

PY - 2015/3/6

Y1 - 2015/3/6

N2 - Purpose: To evaluate low-voltage X-ray stereotactic radiotherapy (SRT) delivered in conjunction with intravitreal ranibizumab for the treatment of active macular polypoidal choroidal vasculopathy (PCV). Methods: At baseline, all eyes received an intravitreal injection of ranibizumab, followed by 16-Gy X-ray SRT to the macula. Further ranibizumab injections were given pro re nata. The primary outcome measure was regression of the polyps assessed by indocyanine green angiography. Secondary outcome measures were best-corrected visual acuity (BCVA) and central foveal thickness (CFT) changes on optical coherence tomography. Local or systemic adverse events were evaluated as well. Results: We examined 12 eyes of 12 patients with PCV. At month 12, an angiographic regression of the polyps was observed in 10 of the 12 eyes. The mean BCVA improved by 7.6 letters: from 65.08 ± 11.4 to 72.7 ± 14.75 letters on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart. The mean CFT decreased from 372.3 ± 79.6 to 215.9 ± 57.9 μm (p <0.01). No local or systemic adverse events were reported. Conclusions: The preliminary data support the safety of low-voltage X-ray SRT for the treatment of macular PCV and show polyp closure, reduction in CFT and improvement in the mean BCVA. Additional research is warranted to confirm the efficacy and longer-term safety of this therapy in this population.

AB - Purpose: To evaluate low-voltage X-ray stereotactic radiotherapy (SRT) delivered in conjunction with intravitreal ranibizumab for the treatment of active macular polypoidal choroidal vasculopathy (PCV). Methods: At baseline, all eyes received an intravitreal injection of ranibizumab, followed by 16-Gy X-ray SRT to the macula. Further ranibizumab injections were given pro re nata. The primary outcome measure was regression of the polyps assessed by indocyanine green angiography. Secondary outcome measures were best-corrected visual acuity (BCVA) and central foveal thickness (CFT) changes on optical coherence tomography. Local or systemic adverse events were evaluated as well. Results: We examined 12 eyes of 12 patients with PCV. At month 12, an angiographic regression of the polyps was observed in 10 of the 12 eyes. The mean BCVA improved by 7.6 letters: from 65.08 ± 11.4 to 72.7 ± 14.75 letters on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart. The mean CFT decreased from 372.3 ± 79.6 to 215.9 ± 57.9 μm (p <0.01). No local or systemic adverse events were reported. Conclusions: The preliminary data support the safety of low-voltage X-ray SRT for the treatment of macular PCV and show polyp closure, reduction in CFT and improvement in the mean BCVA. Additional research is warranted to confirm the efficacy and longer-term safety of this therapy in this population.

KW - Age-related macular degeneration

KW - Indocyanine green angiography

KW - Intravitreal ranibizumab

KW - Polypoidal choroidal vasculopathy

KW - Stereotactic radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=84924225168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924225168&partnerID=8YFLogxK

U2 - 10.1159/000368561

DO - 10.1159/000368561

M3 - Article

C2 - 25402871

AN - SCOPUS:84924225168

VL - 233

SP - 82

EP - 88

JO - Ophthalmologica

JF - Ophthalmologica

SN - 0030-3755

IS - 2

ER -